The investigators created a CD5 CAR-T cell that could secrete IL-15 with the enhanced anti-tumor response, which rapidly and potently improved the condition of a T-NHL patient with CNS involvement in a phase 1 clinical trial with 20 participants enrolled (NCT04594135) and only grade 1 CRS was observed (CTCAE v4.0) [60]. The gene discussed is CD5; the disease is non-Hodgkin lymphoma.